I know the PEA states the figures, but just to clarify, Anson are sitting on approximately 70 years worth of bromine and lithium if both were to be extracted simultaneously at the current rates specified in the PEA? ie (15,000 x avg USD$5268) x 79 years P/T P/A for Bromine and and (2674 x USD$15,000) x 70 years for Lithium?
These are mentioned in the stage 1 figures. Does that mean stage 2 will be more efficient? Eg more processing = less operating years? Plus the other elements they want to extract
Bromine
15,000 x $5280 = $79,200,000 per year
79,200,000 x 78.4 = $6,209,280,000 total over life of mine (6.2 billion) before costs
Lithium
2674 x $15,000 p/t = $40,110,000 per year
40,110,000 x 71.8 = $2,879,898,000 total over life of mine (2.8 billion) before costs
Roughly USD$9 billion at paradox alone without any other minerals considered?
Which means the SP should be at around AUD$10 during production.
My maths might be way off so please correct me.
- Forums
- ASX - By Stock
- ASN
- Ann: Paradox Brine Stage 1 Sodium Bromide/Lithium Updated PEA
Ann: Paradox Brine Stage 1 Sodium Bromide/Lithium Updated PEA, page-81
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ASN (ASX) to my watchlist
(20min delay)
|
|||||
Last
15.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $206.4M |
Open | High | Low | Value | Volume |
15.5¢ | 17.0¢ | 15.0¢ | $298.3K | 1.888M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 228233 | 15.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
15.5¢ | 38878 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
7 | 228233 | 0.150 |
7 | 814500 | 0.145 |
5 | 589149 | 0.140 |
4 | 26592 | 0.135 |
5 | 341545 | 0.130 |
Price($) | Vol. | No. |
---|---|---|
0.155 | 38878 | 2 |
0.160 | 7692 | 1 |
0.165 | 103000 | 2 |
0.170 | 600459 | 18 |
0.175 | 913435 | 10 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
ASN (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online